The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The program is tied to Vertex’s gene-editing therapy Casgevy for sickle cell disease ... treatment in exchange for purchasing its product, and only its product, is meant to induce patients ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell ...

The company's flagship product, Casgevy, developed in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), has garnered significant attention as it represents one of the first gene-edited ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.